Clinical Trials Logo

Coronavirus Infections clinical trials

View clinical trials related to Coronavirus Infections.

Filter by:

NCT ID: NCT04424836 Completed - Clinical trials for Acute Respiratory Failure

HFNC Treatment in COVID-19 Pneumonia

Start date: May 15, 2020
Phase:
Study type: Observational

coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.

NCT ID: NCT04424355 Completed - Pneumonia Clinical Trials

Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.

Start date: May 19, 2020
Phase:
Study type: Observational

Since the onset of the COVID-19 pandemic, the importance of chest computed tomography (CT) in detecting signs of viral pneumonia has become clear from the literature. However, the increased patient flow creates an additional pressure on CT centers. We believe, the use of chest magnetic resonance imaging (MRI) can help to test patients for CОVID-19 when CT scan is not available. Lung MRI may be useful in routing a patient in a difficult epidemiological situation.

NCT ID: NCT04424212 Completed - Clinical trials for Depression and Quality of Life Related to the Coronavirus Pandemic

ICBT for Mental Health Problems Related to the Coronavirus Pandemic

Start date: June 10, 2020
Phase: N/A
Study type: Interventional

The study seeks to investigate the effects of a guided internet-based cognitive behavioral therapy (ICBT) programme a on adult mental health problems related to the current coronavirus pandemic. ICBT will be compared to a wait-list control group. Participants will be recruited in Sweden with a nationwide recruitment.

NCT ID: NCT04424134 Recruiting - COVID 19 Clinical Trials

BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization

BISCUIT
Start date: May 16, 2020
Phase: Phase 3
Study type: Interventional

Patients with mild and severe COVID 19 will be randomized 1:1 into two groups: experimental, which will get bromhexine and spironolactone, and control. Patients will get investigated therapy for ten days. Change in clinical assessment score COVID 19 (CAS COVID 19) between baseline and 12th day will be evaluated as a primary endpoint. Forty-five-day risk of death or mechanical ventilation will also be assessed.

NCT ID: NCT04424017 Completed - COVID Clinical Trials

Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Start date: June 7, 2020
Phase:
Study type: Observational

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

NCT ID: NCT04423991 Completed - COVID-19 Clinical Trials

Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

IDENTIFY
Start date: March 10, 2020
Phase: N/A
Study type: Interventional

The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.

NCT ID: NCT04423315 Completed - Clinical trials for Corona Virus Infection

Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia

Covid-19
Start date: June 8, 2020
Phase:
Study type: Observational

Covid-19 mainly affects the respiratory system. Multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. In this study, the association between thrombosis risk and clinical presentation of Covid-19 is investigated.

NCT ID: NCT04423042 Not yet recruiting - COVID-19 Clinical Trials

Tocilizumab in Coronavirus-19 Positive Patients

Start date: July 30, 2020
Phase: Phase 3
Study type: Interventional

This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19. Patients with COVID-19 are at high risk of life-threatening hyperinflammation and death. One in three COVID-19 patients admitted to ICU was found to develop life-threatening hyperinflammation. The risk of death when untreated is estimated to be 50-80%.

NCT ID: NCT04422535 Recruiting - Clinical trials for Coronavirus Infection

Effects on the Qt Interval of COVID-19 Coronavirus Infection

QT-COVID-19
Start date: May 29, 2020
Phase:
Study type: Observational

The present study aims to evaluate the impact of COVID-19 disease and its treatment on ventricular repolarization, assessed by measuring the QTc interval, in patients admitted to the critical care unit.

NCT ID: NCT04422470 Completed - Clinical trials for Coronavirus Infection and Hematologic Diseases

Registry of Patients With Hematologic Disease and COVID-19 in Russia

CHRONOS19
Start date: June 22, 2020
Phase:
Study type: Observational [Patient Registry]

This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).